Lantern Pharma Q1 net loss $3.9M; cash $51.5M; first patient dosed in Phase 2 Harmonic trial

Lantern Pharma Inc.

2024-Q1 EPS reported -$0.36

Cash, cash equivalents, and marketable securities $51.5M as of March 31, 2023; cash runway into 2025.
Net loss $3.9M ($0.36/share) for Q1 2023 vs $4.1M ($0.38/share) for Q1 2022.
Dosed first patient in Phase 2 Harmonic trial for never-smoker NSCLC; multiple additional sites expected by mid-2023.
IND submission for LP-184 anticipated this week; Phase 1A basket trial targeted for mid-2023 in solid tumors and CNS cancers.
Formed subsidiary Starlight Therapeutics to develop LP-184 (STAR-001) for CNS and brain cancers.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Lantern Pharma Inc. reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

will issue a press release announcing its financial results for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Lantern Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-015941

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.